TITLE

Prognostic factors and clinical outcome of patients with Ewing's sarcoma family of tumors in adults: multicentric study of the Anatolian Society of Medical Oncology

AUTHOR(S)
Arpaci, Erkan; Yetisyigit, Tarkan; Seker, Metin; Uncu, Dogan; Uyeturk, Ummugul; Oksuzoglu, Berna; Demirci, Umut; Coskun, Ugur; Kucukoner, Mehmet; Isıkdogan, Abdurrahman; Inanc, Mevlude; Alkis, Necati; Ozkan, Metin
PUB. DATE
March 2013
SOURCE
Medical Oncology;Mar2013, Vol. 30 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The aim of this study was to evaluate prognostic factors, survival rate and the efficacy of the treatment modalities used in patients with Ewing sarcoma family of tumors (ESFT). Data of patients with ESFTs followed up at different cancer centers in Turkey between 2001 and 2010 were retrospectively analyzed. The median age of 114 patients was 26 years (range 14-66). The median follow-up was 20 months (range 1-118 months). Tumor size was between 1.5 and 14 cm (median 8 cm). Eighty-six percent of patients had localized disease at presentation, and 14 % had metastatic disease. Local therapy was surgery alone in 31 % of patients, surgery combined with radiotherapy in 41 % and radiotherapy alone in 18 %. Approximately 70 % of patients were treated with vincristine, doxorubicin, cyclophosphamide and actinomycin-D, alternating with ifosfamide and etoposide every 3 weeks. In patients with localized disease at presentation, the 5-year disease-free survival and overall survival were 60 and 65 %, respectively. At univariate analysis, patients with tumor size ≥8 cm, high serum lactate dehydrogenase, metastasis at presentation, poor histological response to chemotherapy and positive surgical margin had significantly worse event-free survival. The significant predictors of worse overall survival at univariate analysis were tumor size ≤8 cm, high lactate dehydrogenase, metastasis at presentation, poor histological response to chemotherapy, radiotherapy only as local treatment and positive surgical margin. ESFTs are aggressive tumors with a high incidence of local recurrence and distant metastasis. Multimodality treatment consisting of adequate surgical resection, aggressive chemotherapy (VAC alternating with IE) and radiotherapy is recommended for patients with ESFTs.
ACCESSION #
85859890

 

Related Articles

  • Ewing’s sarcoma and primitive neuroectodermal tumor of hand and forearm. Daecke, Wolfgang; Ahrens, Susanne; Juergens, Herbert; Martini, Abdul-Kader; Ewerbeck, Volker; Kotz, Rainer; Winkelmann, Winfried; Bernd, Ludger // Journal of Cancer Research & Clinical Oncology;Apr2005, Vol. 131 Issue 4, p219 

    Purpose: Because Ewing’s sarcoma (EWS) is extremely rare in the hand and forearm, only limited data are available for planning treatment or predicting prognosis.Methods: Data of 33 patients with EWS of the forearm or hand who were enrolled in studies of the German Association for...

  • P41: Management of Ewing's sarcoma in University Hospital of Casablanca. Dao, A.; Jabir, H.; Motamid, Z.; Sahraoui, S.; Taleb, A.; Bouchbika, Z.; Benchakroun, N.; Tawfiq, N.; Jouhadi, H.; Benider, A. // Clinical Cancer Investigation Journal;2015 Supplement, Vol. 4 Issue S1, pS34 

    Introduction: Ewing sarcomas are rare tumors (3% of malignant tumors in children). Standardized management and multidisciplinary approach is carried in our context for a long time. The purpose of this study was to describe clinical profiles and therapeutic outcomes. Patients and Methods: This is...

  • Role of Radiotherapy in the Multimodal Treatment of Ewing Sarcoma Family Tumors. Yunseon Choi; Do Hoon Lim; Soo Hyun Lee; Chuhl Joo Lyu; Jung Ho Im; Yun-Han Lee; Chang-Ok Suh // Cancer Research & Treatment;Oct2015, Vol. 47 Issue 4, p904 

    Purpose The aim of this study was to evaluate the role of radiotherapy (RT) in the management of Ewing sarcoma family tumors (ESFT). Materials and Methods Retrospective analysis was performed on 91 patients with localized ESFT treated from 1988 to 2012. Primary tumor size was ≥ 8 cm in 33...

  • State-of-the-art approach in selective curable tumors: bone sarcoma. Bielack, S. S.; Carrle, D. // Annals of Oncology;Sep2008 Supplement 7, Vol. 19, p155 

    The article discusses the state-of-the-art treatment for bone sarcoma. It states that osteosarcoma and Ewing tumors need multidisciplinary treatment approaches. It mentions that less than one-third of those with primary metastases can be treated by regimens including multidrug chemotherapy,...

  • Periosteal Ewing's sarcoma: report of two new cases and review of the literature. Kollender, Yehuda; Shabat, Shay; Nirkin, Alexander; Issakov, Josephine; Flusser, Gideon; Merimsky, Ofer; Meller, Isaac // Sarcoma;Sep1999, Vol. 3 Issue 2, p85 

    Background. The origin of Ewing's sarcoma in a periosteal location is rare and not clearly documented. Other malignant bone tumors appear to have a somewhat better prognosis when confined between periosteum and bone. Is it the same for periosteal Ewing's sarcoma? Methods. We describe two new...

  • Re: Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity. Tamborini, Elena; Bonadiman, Lorena; Albertini, Veronica; Pierotti, Marco A.; Pilotti, Silvana // JNCI: Journal of the National Cancer Institute;7/16/2003, Vol. 95 Issue 14, p1087 

    Comments on previous articles published in the 'Journal of the National Cancer Institute' regarding the potential use of imatinib in Ewing's sarcoma. Molecular characterization of surgical specimens of primary and metastatic Ewing's sarcomas; Indication that a KIT-mediated autocrine loop in...

  • RESPONSE. Merchant, Melinda S.; Thiele, Carol J. // JNCI: Journal of the National Cancer Institute;7/16/2003, Vol. 95 Issue 14, p1088 

    Responds to comments on previous articles published in the 'Journal of the National Cancer Institute' regarding the potential use of imatinib in Ewing's sarcoma. Agreement that the potential efficacy of imatinib should not be limited to gain-of-function mutations; Need for further studies to...

  • Initial Symptoms and Clinical Features in Osteosarcoma and Ewing Sarcoma. Widhe, Bjorn; Widhe, Torulf // Journal of Bone & Joint Surgery, American Volume;May2000, Vol. 82-A Issue 5, p667 

    Background: The time between the initial symptoms of osteosarcoma and Ewing sarcoma and the correct diagnosis and treatment is long. Over the last two decades, the prognosis for patients with these diseases has dramatically improved due to a new chemotherapy regimen. As a consequence, a...

  • Bilateral endoprosthetic replacements of the proximal femur. Foukas, Athanasios F.; Grimer, Robert J. // Sarcoma;Mar1998, Vol. 2 Issue 1, p49 

    Patient . We report the case of a 20-year-old caucasian male with an Ewing's sarcoma in the left upper femur. After induction chemotherapy, he underwent resection of the left upper femur and insertion of a cemented proximal femoral replacement. Four years later, he presented with a solitary bone...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics